OSE Immunotherapeutics S.A.
OSE.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €1,323 | €831 | €82,573 | €869 |
| % Growth | 59.2% | -99% | 9,402.1% | – |
| Cost of Goods Sold | €0 | €831 | €0 | €0 |
| Gross Profit | €0 | €862 | €69,046 | €869 |
| % Margin | 0% | 103.7% | 83.6% | 100% |
| R&D Expenses | €16,611 | €18,282 | €16,065 | €9,736 |
| G&A Expenses | €0 | €2,163 | €4,097 | €2,388 |
| SG&A Expenses | €6,568 | €3,890 | €5,190 | €3,690 |
| Sales & Mktg Exp. | €0 | €1,727 | €1,082 | €1,302 |
| Other Operating Expenses | €0 | -€1,721 | -€2,003 | -€1,101 |
| Operating Expenses | €23,179 | €20,451 | €19,252 | €12,325 |
| Operating Income | -€23,488 | -€19,586 | €46,127 | -€13,152 |
| % Margin | -1,775.4% | -2,356.9% | 55.9% | -1,513.5% |
| Other Income/Exp. Net | €5,310 | -€1,297 | €10,981 | -€1,463 |
| Pre-Tax Income | -€18,178 | -€20,883 | €57,108 | -€14,615 |
| Tax Expense | -€3,073 | -€1,153 | €3,540 | -€3,472 |
| Net Income | -€15,105 | -€19,730 | €57,175 | -€11,143 |
| % Margin | -1,141.7% | -2,374.2% | 69.2% | -1,282.3% |
| EPS | -0.68 | -0.91 | 2.63 | -0.54 |
| % Growth | 25.3% | -134.6% | 587% | – |
| EPS Diluted | -0.68 | -0.91 | 2.63 | -0.54 |
| Weighted Avg Shares Out | 22,118 | 21,667 | 21,759 | 20,670 |
| Weighted Avg Shares Out Dil | 22,118 | 21,667 | 21,759 | 20,500 |
| Supplemental Information | – | – | – | – |
| Interest Income | €508 | €1,142 | €325 | €2,107 |
| Interest Expense | €1,699 | €1,437 | €1,865 | €1,361 |
| Depreciation & Amortization | €1,632 | €1,699 | €1,664 | €1,696 |
| EBITDA | -€14,848 | -€19,442 | €60,637 | -€11,701 |
| % Margin | -1,122.3% | -2,339.6% | 73.4% | -1,346.5% |